[
  {
    "ts": "2026-01-07T02:10:00+00:00",
    "headline": "Best Peptides for Weight Loss 2026: Oral Wegovy Launch Expands GLP-1 Format Options as Telehealth Platforms Compare FDA-Approved vs Compounded Semaglutide Access",
    "summary": "Following Oral Wegovy Introduction, Consumer Analysis Examines Injectable vs Oral Semaglutide Pricing, Compounded Tirzepatide Access Through Direct Meds, and Three-Entity Telehealth Platform StructureHOUSTON, TX, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This article is for informational purposes only. It is not medical advice. Medical decisions about prescription weight-management treatments are appropriately made with a qualified clinician who can evaluate individual risks and eligibility.",
    "url": "https://finance.yahoo.com/news/best-peptides-weight-loss-2026-021000107.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "575dbca8-b996-3188-9676-aa0919f8349f",
      "content": {
        "id": "575dbca8-b996-3188-9676-aa0919f8349f",
        "contentType": "STORY",
        "title": "Best Peptides for Weight Loss 2026: Oral Wegovy Launch Expands GLP-1 Format Options as Telehealth Platforms Compare FDA-Approved vs Compounded Semaglutide Access",
        "description": "",
        "summary": "Following Oral Wegovy Introduction, Consumer Analysis Examines Injectable vs Oral Semaglutide Pricing, Compounded Tirzepatide Access Through Direct Meds, and Three-Entity Telehealth Platform StructureHOUSTON, TX, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This article is for informational purposes only. It is not medical advice. Medical decisions about prescription weight-management treatments are appropriately made with a qualified clinician who can evaluate individual risks and eligibility.",
        "pubDate": "2026-01-07T02:10:00Z",
        "displayTime": "2026-01-07T02:10:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/df21957acdd7c42436e3aaedec558622",
          "originalWidth": 160,
          "originalHeight": 37,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/xS8T3RYGrDPJRFqfUJN7LQ--~B/aD0zNzt3PTE2MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/df21957acdd7c42436e3aaedec558622.cf.webp",
              "width": 160,
              "height": 37,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/039gIHMOyF50T_.LvM5i0Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/df21957acdd7c42436e3aaedec558622.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/best-peptides-weight-loss-2026-021000107.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/best-peptides-weight-loss-2026-021000107.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-07T01:50:00+00:00",
    "headline": "Warning: This Skyrocketing Stock Has a Hidden Risk",
    "summary": "Novo Nordisk's new GLP-1 pill highlights the risk that Eli Lilly faces, as investors reward it for being at the forefront of the weight loss market.",
    "url": "https://www.fool.com/investing/2026/01/06/warning-skyrocketing-stock-hidden-risk-lly/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "65266ece-00cb-340b-8630-4a3b1a187036",
      "content": {
        "id": "65266ece-00cb-340b-8630-4a3b1a187036",
        "contentType": "STORY",
        "title": "Warning: This Skyrocketing Stock Has a Hidden Risk",
        "description": "",
        "summary": "Novo Nordisk's new GLP-1 pill highlights the risk that Eli Lilly faces, as investors reward it for being at the forefront of the weight loss market.",
        "pubDate": "2026-01-07T01:50:00Z",
        "displayTime": "2026-01-07T01:50:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/9e232c91e4847823108a7df0acac4130",
          "originalWidth": 1200,
          "originalHeight": 800,
          "caption": "People in business attire leaving the starting line on a track.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/CDRGF1muIS2SuyvzghsAVg--~B/aD04MDA7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/9e232c91e4847823108a7df0acac4130.cf.webp",
              "width": 1200,
              "height": 800,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/5jDXQKQhPaRHYHTl3MeuJA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/9e232c91e4847823108a7df0acac4130.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/01/06/warning-skyrocketing-stock-hidden-risk-lly/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/warning-skyrocketing-stock-hidden-risk-015000651.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-07T10:50:28+00:00",
    "headline": "Trending tickers: Micron, Sandisk Corporation, Ventyx Biosciences, BP and Reckitt",
    "summary": "The latest investor updates on stocks that are trending on Wednesday.",
    "url": "https://uk.finance.yahoo.com/news/micron-sandisk-corporation-ventyx-biosciences-bp-reckitt-trending-tickers-105028144.html",
    "source": "Yahoo Finance UK",
    "provider": "yfinance",
    "raw": {
      "id": "cf806b0e-7f4e-402e-9fc6-3ae7589d9b5a",
      "content": {
        "id": "cf806b0e-7f4e-402e-9fc6-3ae7589d9b5a",
        "contentType": "STORY",
        "title": "Trending tickers: Micron, Sandisk Corporation, Ventyx Biosciences, BP and Reckitt",
        "description": "",
        "summary": "The latest investor updates on stocks that are trending on Wednesday.",
        "pubDate": "2026-01-07T10:50:28Z",
        "displayTime": "2026-01-07T10:50:28Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/os/creatr-uploaded-images/2026-01/e54a36b0-eba6-11f0-93f7-69524f11062e",
          "originalWidth": 4874,
          "originalHeight": 3077,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/gC5bsfuBa4t6QvJQWAjrNQ--~B/aD0zMDc3O3c9NDg3NDthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/os/creatr-uploaded-images/2026-01/e54a36b0-eba6-11f0-93f7-69524f11062e.cf.webp",
              "width": 4874,
              "height": 3077,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kDHMPJbFVj4Bk_Pij2j_2w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/os/creatr-uploaded-images/2026-01/e54a36b0-eba6-11f0-93f7-69524f11062e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Yahoo Finance UK",
          "url": "http://uk.finance.yahoo.com/"
        },
        "canonicalUrl": {
          "url": "https://uk.finance.yahoo.com/news/micron-sandisk-corporation-ventyx-biosciences-bp-reckitt-trending-tickers-105028144.html",
          "site": "finance",
          "region": "GB",
          "lang": "en-GB"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/micron-sandisk-corporation-ventyx-biosciences-bp-reckitt-trending-tickers-105028144.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MU"
            },
            {
              "symbol": "SNDK"
            },
            {
              "symbol": "VTYX"
            },
            {
              "symbol": "RKT.L"
            },
            {
              "symbol": "BP.L"
            },
            {
              "symbol": "CL=F"
            },
            {
              "symbol": "WDC"
            },
            {
              "symbol": "^FTSE"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "000660.KS"
            },
            {
              "symbol": "005930.KS"
            },
            {
              "symbol": "STX"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-07T12:13:34+00:00",
    "headline": "Eli Lilly Nears Deal to Buy Ventyx Biosciences for Over $1 Billion",
    "summary": "Biotech acquisition would expand Lilly's pipeline in inflammatory and metabolic diseases",
    "url": "https://finance.yahoo.com/news/eli-lilly-nears-deal-buy-121334624.html",
    "source": "GuruFocus.com",
    "provider": "yfinance",
    "raw": {
      "id": "e9d69a5d-fe20-3a75-ab6c-7ad80abb3a91",
      "content": {
        "id": "e9d69a5d-fe20-3a75-ab6c-7ad80abb3a91",
        "contentType": "STORY",
        "title": "Eli Lilly Nears Deal to Buy Ventyx Biosciences for Over $1 Billion",
        "description": "",
        "summary": "Biotech acquisition would expand Lilly's pipeline in inflammatory and metabolic diseases",
        "pubDate": "2026-01-07T12:13:34Z",
        "displayTime": "2026-01-07T12:13:34Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/us.finance.gurufocus/434a82c75d97e3a5a22898838638d64c",
          "originalWidth": 6382,
          "originalHeight": 4786,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Klfzvp39.soPeoaiqKcS3w--~B/aD00Nzg2O3c9NjM4MjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/us.finance.gurufocus/434a82c75d97e3a5a22898838638d64c.cf.webp",
              "width": 6382,
              "height": 4786,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/W9CEpukOrGiNcDXN4UIi7Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/434a82c75d97e3a5a22898838638d64c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GuruFocus.com",
          "url": "http://www.gurufocus.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-nears-deal-buy-121334624.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-nears-deal-buy-121334624.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "VTYX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-07T12:13:20+00:00",
    "headline": "Is Eli Lilly (LLY) Still Sensibly Priced After Its Strong Multi Year Share Price Run",
    "summary": "If you are wondering whether Eli Lilly's share price still makes sense after a long run up, or if the stock is starting to look stretched, this article walks through what the current market price could be implying about value. The stock most recently closed at US$1,064.04, with a 1.5% decline over the last 7 days, a 5.3% gain over the last 30 days, a 1.5% decline year to date, a 38.6% return over 1 year and a very large 5-year return that is well above 7x. Recent coverage of Eli Lilly has...",
    "url": "https://finance.yahoo.com/news/eli-lilly-lly-still-sensibly-121320690.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "88034f23-eb06-3981-bf93-95009dc4befc",
      "content": {
        "id": "88034f23-eb06-3981-bf93-95009dc4befc",
        "contentType": "STORY",
        "title": "Is Eli Lilly (LLY) Still Sensibly Priced After Its Strong Multi Year Share Price Run",
        "description": "",
        "summary": "If you are wondering whether Eli Lilly's share price still makes sense after a long run up, or if the stock is starting to look stretched, this article walks through what the current market price could be implying about value. The stock most recently closed at US$1,064.04, with a 1.5% decline over the last 7 days, a 5.3% gain over the last 30 days, a 1.5% decline year to date, a 38.6% return over 1 year and a very large 5-year return that is well above 7x. Recent coverage of Eli Lilly has...",
        "pubDate": "2026-01-07T12:13:20Z",
        "displayTime": "2026-01-07T12:13:20Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/uZWvuDuy6_Wr6cKvxAFZcw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/g78F5NO5pySOmBHzFi6.eA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-lly-still-sensibly-121320690.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-lly-still-sensibly-121320690.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-07T12:00:00+00:00",
    "headline": "Mediar Therapeutics Announces Oversubscribed $76 Million Series B Financing and Clinical Advancement of First-in-Class Fibrosis Portfolio",
    "summary": "Mediar Therapeutics, Inc., a clinical-stage biotechnology company advancing first-in-class therapies designed to halt fibrosis, today announced an oversubscribed $76 million Series B financing co-led by Amplitude Ventures and ICG, with participation from new investors Longwood Fund, Asahi Kasei Pharma Ventures, Alexandria Real Estate Trust (ARE), and existing Series A investors. Joining the Mediar board from Amplitude Ventures is Bharat Srinivasa, PhD, and from ICG is Allan Marchington, PhD. Pro",
    "url": "https://finance.yahoo.com/news/mediar-therapeutics-announces-oversubscribed-76-120000921.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "b94db6d7-0489-3964-a2a5-38498313685b",
      "content": {
        "id": "b94db6d7-0489-3964-a2a5-38498313685b",
        "contentType": "STORY",
        "title": "Mediar Therapeutics Announces Oversubscribed $76 Million Series B Financing and Clinical Advancement of First-in-Class Fibrosis Portfolio",
        "description": "",
        "summary": "Mediar Therapeutics, Inc., a clinical-stage biotechnology company advancing first-in-class therapies designed to halt fibrosis, today announced an oversubscribed $76 million Series B financing co-led by Amplitude Ventures and ICG, with participation from new investors Longwood Fund, Asahi Kasei Pharma Ventures, Alexandria Real Estate Trust (ARE), and existing Series A investors. Joining the Mediar board from Amplitude Ventures is Bharat Srinivasa, PhD, and from ICG is Allan Marchington, PhD. Pro",
        "pubDate": "2026-01-07T12:00:00Z",
        "displayTime": "2026-01-07T12:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/6024aabeb42cccbade6e46ac9a1d4ca3",
          "originalWidth": 400,
          "originalHeight": 150,
          "caption": "Mediar Therapeutics logo (PRNewsfoto/Mediar Therapeutics)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/J.Y1EFIP6VAquwc3xHxu8w--~B/aD0xNTA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/6024aabeb42cccbade6e46ac9a1d4ca3.cf.webp",
              "width": 400,
              "height": 150,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/gwbhFt2ZTLm6QzvY77mBKQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/6024aabeb42cccbade6e46ac9a1d4ca3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/mediar-therapeutics-announces-oversubscribed-76-120000921.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/mediar-therapeutics-announces-oversubscribed-76-120000921.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-07T11:34:47+00:00",
    "headline": "Stocks to Watch Wednesday: Strategy, Applied Digital, Ventyx, Mobileye",
    "summary": "‚ÜóÔ∏è Strategy (MSTR): Index provider MSCI said it won't exclude crypto treasury companies from its indexes. Shares of bitcoin accumulator Strategy climbed 4% in premarket trading. ‚ÜòÔ∏è Newmont (NEM), Freeport-McMoRan (FCX), Antofagasta (UK: ANTO): Global mining stocks came under pressure as a rally in precious and industrial metals stalled.",
    "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-01-07-2026/card/stocks-to-watch-wednesday-strategy-newmont-caterpillar-zsZqDS9uY17bxWVWaoiH?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "88cdf999-420b-3e40-85e4-c591190aabda",
      "content": {
        "id": "88cdf999-420b-3e40-85e4-c591190aabda",
        "contentType": "STORY",
        "title": "Stocks to Watch Wednesday: Strategy, Applied Digital, Ventyx, Mobileye",
        "description": "",
        "summary": "‚ÜóÔ∏è Strategy (MSTR): Index provider MSCI said it won't exclude crypto treasury companies from its indexes. Shares of bitcoin accumulator Strategy climbed 4% in premarket trading. ‚ÜòÔ∏è Newmont (NEM), Freeport-McMoRan (FCX), Antofagasta (UK: ANTO): Global mining stocks came under pressure as a rally in precious and industrial metals stalled.",
        "pubDate": "2026-01-07T11:34:47Z",
        "displayTime": "2026-01-07T11:34:47Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/88cdf999-420b-3e40-85e4-c591190aabda/stocks-to-watch-wednesday-.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/88cdc7803b870291daefe4b4f1eaeed3",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/LBNZqD1vSZ3knEFLkyzdJw--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/88cdc7803b870291daefe4b4f1eaeed3.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/0Ww64e.65AiKwuQtcYwB0w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/88cdc7803b870291daefe4b4f1eaeed3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-01-07-2026/card/stocks-to-watch-wednesday-strategy-newmont-caterpillar-zsZqDS9uY17bxWVWaoiH?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MBLY"
            },
            {
              "symbol": "ANFGF"
            },
            {
              "symbol": "005380.KS"
            },
            {
              "symbol": "005385.KS"
            },
            {
              "symbol": "005387.KS"
            },
            {
              "symbol": "005389.KS"
            },
            {
              "symbol": "CVX"
            },
            {
              "symbol": "MSTR"
            },
            {
              "symbol": "VTYX"
            },
            {
              "symbol": "BTC-USD"
            },
            {
              "symbol": "APLD"
            },
            {
              "symbol": "NEM"
            },
            {
              "symbol": "FCX"
            },
            {
              "symbol": "QTCI"
            },
            {
              "symbol": "LKOH.ME"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-07T13:12:02+00:00",
    "headline": "How The Narrative Around Nektar Therapeutics (NKTR) Is Shifting With Rezpeg Data And Litigation Risks",
    "summary": "Nektar Therapeutics just saw its fair value model refreshed, with the headline number holding steady at US$114.43 per share even as the long term revenue growth assumption for Rezpeg edged to a 10.83% decline. This reflects a slightly less negative view of future sales potential tied to upcoming clinical data and Alopecia Areata optionality. Behind that small shift is a tug of war in Street research between bullish views that Rezpeg‚Äôs clinical profile could support higher long term revenue...",
    "url": "https://finance.yahoo.com/news/narrative-around-nektar-therapeutics-nktr-131202192.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "645da412-461a-30fe-9f51-de2da851a5d3",
      "content": {
        "id": "645da412-461a-30fe-9f51-de2da851a5d3",
        "contentType": "STORY",
        "title": "How The Narrative Around Nektar Therapeutics (NKTR) Is Shifting With Rezpeg Data And Litigation Risks",
        "description": "",
        "summary": "Nektar Therapeutics just saw its fair value model refreshed, with the headline number holding steady at US$114.43 per share even as the long term revenue growth assumption for Rezpeg edged to a 10.83% decline. This reflects a slightly less negative view of future sales potential tied to upcoming clinical data and Alopecia Areata optionality. Behind that small shift is a tug of war in Street research between bullish views that Rezpeg‚Äôs clinical profile could support higher long term revenue...",
        "pubDate": "2026-01-07T13:12:02Z",
        "displayTime": "2026-01-07T13:12:02Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/pVOKMAerbRsXv56pHka6Lw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/EmyGBi4taxQExvvwka_9KQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/narrative-around-nektar-therapeutics-nktr-131202192.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/narrative-around-nektar-therapeutics-nktr-131202192.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NKTR"
            },
            {
              "symbol": "WSFX.BO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-07T13:00:00+00:00",
    "headline": "Recludix Pharma to Present at the Annual J.P. Morgan Healthcare Conference",
    "summary": "SAN DIEGO, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Recludix Pharma, a clinical-stage company leading the discovery and development of inhibitors of challenging targets for inflammatory disease, today announced that Nancy Whiting, Pharm.D., president and chief executive officer of Recludix, will present an overview of the company‚Äôs progress at the Annual J.P. Morgan Healthcare Conference in San Francisco, CA. The company‚Äôs presentation will be on Thursday, January 15, 2026, at 9:30 a.m. Pacific Time. A",
    "url": "https://finance.yahoo.com/news/recludix-pharma-present-annual-j-130000115.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "6e95b609-3902-3e4c-9a98-c979e669d3cc",
      "content": {
        "id": "6e95b609-3902-3e4c-9a98-c979e669d3cc",
        "contentType": "STORY",
        "title": "Recludix Pharma to Present at the Annual J.P. Morgan Healthcare Conference",
        "description": "",
        "summary": "SAN DIEGO, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Recludix Pharma, a clinical-stage company leading the discovery and development of inhibitors of challenging targets for inflammatory disease, today announced that Nancy Whiting, Pharm.D., president and chief executive officer of Recludix, will present an overview of the company‚Äôs progress at the Annual J.P. Morgan Healthcare Conference in San Francisco, CA. The company‚Äôs presentation will be on Thursday, January 15, 2026, at 9:30 a.m. Pacific Time. A",
        "pubDate": "2026-01-07T13:00:00Z",
        "displayTime": "2026-01-07T13:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/3e3b7f225a2b77a1d1ea7d5025f01be2",
          "originalWidth": 842,
          "originalHeight": 325,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YBxgqYBDasfFycfbK8bENQ--~B/aD0zMjU7dz04NDI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/3e3b7f225a2b77a1d1ea7d5025f01be2.cf.webp",
              "width": 842,
              "height": 325,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/knUi1j71UOIuwB0719OEbg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/3e3b7f225a2b77a1d1ea7d5025f01be2.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/recludix-pharma-present-annual-j-130000115.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/recludix-pharma-present-annual-j-130000115.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BPMC"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-07T13:00:00+00:00",
    "headline": "BigHat Biosciences Partners With Lilly to Advance Machine-Learning-Enabled Biologics Discovery Through Lilly TuneLab",
    "summary": "SAN MATEO, Calif., January 07, 2026--BigHat Biosciences, a protein therapeutics company that combines state-of-the-art AI models with a high-speed automated wet lab, today announced a collaboration with Eli Lilly and Company (Lilly) focused on advancing machine-learning-enabled biologics discovery through Lilly TuneLab. This project expands BigHat‚Äôs relationship with Lilly, which includes a previously disclosed collaboration focused on the discovery and engineering of next-generation antibody th",
    "url": "https://finance.yahoo.com/news/bighat-biosciences-partners-lilly-advance-130000823.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "1d059e65-fdcd-31f6-9533-35781731b41f",
      "content": {
        "id": "1d059e65-fdcd-31f6-9533-35781731b41f",
        "contentType": "STORY",
        "title": "BigHat Biosciences Partners With Lilly to Advance Machine-Learning-Enabled Biologics Discovery Through Lilly TuneLab",
        "description": "",
        "summary": "SAN MATEO, Calif., January 07, 2026--BigHat Biosciences, a protein therapeutics company that combines state-of-the-art AI models with a high-speed automated wet lab, today announced a collaboration with Eli Lilly and Company (Lilly) focused on advancing machine-learning-enabled biologics discovery through Lilly TuneLab. This project expands BigHat‚Äôs relationship with Lilly, which includes a previously disclosed collaboration focused on the discovery and engineering of next-generation antibody th",
        "pubDate": "2026-01-07T13:00:00Z",
        "displayTime": "2026-01-07T13:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/966b917d27c4abb4960089bbcda04f05",
          "originalWidth": 2018,
          "originalHeight": 504,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/bZcNLaKRkv.pPMyeTlh9Pw--~B/aD01MDQ7dz0yMDE4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/966b917d27c4abb4960089bbcda04f05.cf.webp",
              "width": 2018,
              "height": 504,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/mu2BDKHUARbS6bQKH5q2fA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/966b917d27c4abb4960089bbcda04f05.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bighat-biosciences-partners-lilly-advance-130000823.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bighat-biosciences-partners-lilly-advance-130000823.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-07T12:49:34+00:00",
    "headline": "Eli Lilly signs $1.3bn obesity-focused research deal with Nimbus",
    "summary": "Nimbus will apply its computational chemistry and structure-based drug design to a discovery programme in obesity treatment.",
    "url": "https://www.pharmaceutical-technology.com/news/eli-lilly-signs-1-3bn-obesity-focused-research-deal-with-nimbus/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "b1def73b-3d8e-36a6-9af4-db12d7c970d4",
      "content": {
        "id": "b1def73b-3d8e-36a6-9af4-db12d7c970d4",
        "contentType": "STORY",
        "title": "Eli Lilly signs $1.3bn obesity-focused research deal with Nimbus",
        "description": "",
        "summary": "Nimbus will apply its computational chemistry and structure-based drug design to a discovery programme in obesity treatment.",
        "pubDate": "2026-01-07T12:49:34Z",
        "displayTime": "2026-01-07T12:49:34Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/f423b36c4360ee33bb7b961a76acc5c2",
          "originalWidth": 1000,
          "originalHeight": 666,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kUWtuyWQftcdQ3151t4bJA--~B/aD02NjY7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/f423b36c4360ee33bb7b961a76acc5c2.cf.webp",
              "width": 1000,
              "height": 666,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/5MR6O7FDgqX4ZfHXy.DAmQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/f423b36c4360ee33bb7b961a76acc5c2.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/news/eli-lilly-signs-1-3bn-obesity-focused-research-deal-with-nimbus/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-signs-1-3bn-124934998.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-07T12:22:40+00:00",
    "headline": "Arrowhead‚Äôs RNAi-based obesity drug combo shows benefit in Phase I/IIa trial",
    "summary": "Arrowhead‚Äôs stock rose 6% on market open after the announcement though continued to rise throughout the day.",
    "url": "https://www.clinicaltrialsarena.com/news/arrowheads-rnai-based-obesity-drug-combo-shows-benefit-in-phase-i-iia-trial/",
    "source": "Clinical Trials Arena",
    "provider": "yfinance",
    "raw": {
      "id": "d2bfe94c-fc48-3aeb-839c-f29cabd90d50",
      "content": {
        "id": "d2bfe94c-fc48-3aeb-839c-f29cabd90d50",
        "contentType": "STORY",
        "title": "Arrowhead‚Äôs RNAi-based obesity drug combo shows benefit in Phase I/IIa trial",
        "description": "",
        "summary": "Arrowhead‚Äôs stock rose 6% on market open after the announcement though continued to rise throughout the day.",
        "pubDate": "2026-01-07T12:22:40Z",
        "displayTime": "2026-01-07T12:22:40Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/clinical_trials_arena_396/dd0544913030740ae59f8d3ea6d728f0",
          "originalWidth": 2560,
          "originalHeight": 1874,
          "caption": "Arrowhead is investigating two RNAi candidates in obesity trials. Image credit: Visual Generation / Shutterstock.com",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/mQjw5ytsoOlzTuUQNFCu8A--~B/aD0xODc0O3c9MjU2MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/clinical_trials_arena_396/dd0544913030740ae59f8d3ea6d728f0.cf.webp",
              "width": 2560,
              "height": 1874,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kCnqR1altqVAafosV4ydvA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/clinical_trials_arena_396/dd0544913030740ae59f8d3ea6d728f0.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Clinical Trials Arena",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.clinicaltrialsarena.com/news/arrowheads-rnai-based-obesity-drug-combo-shows-benefit-in-phase-i-iia-trial/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/arrowhead-rnai-based-obesity-drug-122240307.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-07T14:11:30+00:00",
    "headline": "Investors Digest Labor Market Data as US Equity Futures Tread Water Pre-Bell",
    "summary": "US equity futures were flat ahead of Wednesday's opening bell as traders digested labor market data.",
    "url": "https://finance.yahoo.com/news/investors-digest-labor-market-data-141130575.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "5180f574-a4dc-356e-af0a-67bf0b14393d",
      "content": {
        "id": "5180f574-a4dc-356e-af0a-67bf0b14393d",
        "contentType": "STORY",
        "title": "Investors Digest Labor Market Data as US Equity Futures Tread Water Pre-Bell",
        "description": "",
        "summary": "US equity futures were flat ahead of Wednesday's opening bell as traders digested labor market data.",
        "pubDate": "2026-01-07T14:11:30Z",
        "displayTime": "2026-01-07T14:11:30Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/investors-digest-labor-market-data-141130575.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/investors-digest-labor-market-data-141130575.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CL=F"
            },
            {
              "symbol": "VTYX"
            },
            {
              "symbol": "^SPX"
            },
            {
              "symbol": "APOG"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "^DJI"
            },
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "^IXIC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-07T13:13:06+00:00",
    "headline": "Stocks to Watch Wednesday: BP, Netflix, Paramount, Strategy",
    "summary": "üîé Warner Bros. Discovery (WBD): The entertainment conglomerate told shareholders to reject Paramount (PSKY)‚Äôs amended hostile bid for the company, saying its existing deal with Netflix (NFLX) is stronger.",
    "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-01-07-2026/card/stocks-to-watch-wednesday-strategy-newmont-caterpillar-zsZqDS9uY17bxWVWaoiH?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "88cdf999-420b-3e40-85e4-c591190aabda",
      "content": {
        "id": "88cdf999-420b-3e40-85e4-c591190aabda",
        "contentType": "STORY",
        "title": "Stocks to Watch Wednesday: BP, Netflix, Paramount, Strategy",
        "description": "",
        "summary": "üîé Warner Bros. Discovery (WBD): The entertainment conglomerate told shareholders to reject Paramount (PSKY)‚Äôs amended hostile bid for the company, saying its existing deal with Netflix (NFLX) is stronger.",
        "pubDate": "2026-01-07T13:13:06Z",
        "displayTime": "2026-01-07T13:13:06Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/88cdf999-420b-3e40-85e4-c591190aabda/stocks-to-watch-wednesday-.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/88cdc7803b870291daefe4b4f1eaeed3",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/LBNZqD1vSZ3knEFLkyzdJw--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/88cdc7803b870291daefe4b4f1eaeed3.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/0Ww64e.65AiKwuQtcYwB0w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/88cdc7803b870291daefe4b4f1eaeed3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-01-07-2026/card/stocks-to-watch-wednesday-strategy-newmont-caterpillar-zsZqDS9uY17bxWVWaoiH?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MSTR"
            },
            {
              "symbol": "ANFGF"
            },
            {
              "symbol": "005380.KS"
            },
            {
              "symbol": "005385.KS"
            },
            {
              "symbol": "005387.KS"
            },
            {
              "symbol": "005389.KS"
            },
            {
              "symbol": "MBLY"
            },
            {
              "symbol": "BP"
            },
            {
              "symbol": "BTC-USD"
            },
            {
              "symbol": "NEM"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "GME31248-USD"
            },
            {
              "symbol": "VTYX"
            },
            {
              "symbol": "FCX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-07T16:30:00+00:00",
    "headline": "Biotechnology Instruments Market Projected to Reach US$ 141.70 Billion by 2035 | Astute Analytica",
    "summary": "The market offers explosive potential as biology transitions to factory-scale production. Anchored by the USD 100 genome and high-margin consumables, the sector promises sustained scalability. Massive infrastructure investments, like Eli Lilly‚Äôs USD 4.5 billion campus, confirm a lucrative, long-term trajectory.Chicago, Jan. 07, 2026 (GLOBE NEWSWIRE) -- The global biotechnology instruments market size stood at USD 92.12 billion in 2025 and is expected to reach USD 141.70 billion by 2035 with a 4.",
    "url": "https://finance.yahoo.com/news/biotechnology-instruments-market-projected-reach-163000494.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "28ed8e73-126e-3e6d-ace4-ba46acfa4567",
      "content": {
        "id": "28ed8e73-126e-3e6d-ace4-ba46acfa4567",
        "contentType": "STORY",
        "title": "Biotechnology Instruments Market Projected to Reach US$ 141.70 Billion by 2035 | Astute Analytica",
        "description": "",
        "summary": "The market offers explosive potential as biology transitions to factory-scale production. Anchored by the USD 100 genome and high-margin consumables, the sector promises sustained scalability. Massive infrastructure investments, like Eli Lilly‚Äôs USD 4.5 billion campus, confirm a lucrative, long-term trajectory.Chicago, Jan. 07, 2026 (GLOBE NEWSWIRE) -- The global biotechnology instruments market size stood at USD 92.12 billion in 2025 and is expected to reach USD 141.70 billion by 2035 with a 4.",
        "pubDate": "2026-01-07T16:30:00Z",
        "displayTime": "2026-01-07T16:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/c69505cf1983c21fb029b9444d820471",
          "originalWidth": 300,
          "originalHeight": 300,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/JHwPm5XOBkH6S4g8iMmLiw--~B/aD0zMDA7dz0zMDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/c69505cf1983c21fb029b9444d820471.cf.webp",
              "width": 300,
              "height": 300,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/SbelUm4u7tLxgdG5STxR1A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/c69505cf1983c21fb029b9444d820471.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/biotechnology-instruments-market-projected-reach-163000494.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/biotechnology-instruments-market-projected-reach-163000494.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "TMO"
            },
            {
              "symbol": "ILMN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-07T14:36:00+00:00",
    "headline": "Eli Lilly Nears Deal for Biotech Ventyx",
    "summary": "Eli Lilly  is in advanced talks to acquire  Ventyx Biosciences  for around $1 billion, according to people familiar with the matter.  A deal for Ventyx, which specializes in developing pills that can treat inflammatory diseases, could come as soon as Wednesday, the people said.  Ventyx, of San Diego, had a market value of a little over $500 million as of Tuesday afternoon.",
    "url": "https://www.wsj.com/health/pharma/eli-lilly-nears-deal-for-biotech-ventyx-3bc666d2?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "51df9a4d-3de9-3571-be26-6d5f895b92c4",
      "content": {
        "id": "51df9a4d-3de9-3571-be26-6d5f895b92c4",
        "contentType": "STORY",
        "title": "Eli Lilly Nears Deal for Biotech Ventyx",
        "description": "",
        "summary": "Eli Lilly  is in advanced talks to acquire  Ventyx Biosciences  for around $1 billion, according to people familiar with the matter.  A deal for Ventyx, which specializes in developing pills that can treat inflammatory diseases, could come as soon as Wednesday, the people said.  Ventyx, of San Diego, had a market value of a little over $500 million as of Tuesday afternoon.",
        "pubDate": "2026-01-07T14:36:00Z",
        "displayTime": "2026-01-07T14:36:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/51df9a4d-3de9-3571-be26-6d5f895b92c4/eli-lilly-nears-deal-for.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/7639a479b4889ccdcfd06dfdc20c2470",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/3ENIEx0pWOH.W4O48ezfAg--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/7639a479b4889ccdcfd06dfdc20c2470.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/voNRAHQNLLEeD1JApd7V1Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/7639a479b4889ccdcfd06dfdc20c2470.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/health/pharma/eli-lilly-nears-deal-for-biotech-ventyx-3bc666d2?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VTYX"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-07T16:21:28+00:00",
    "headline": "Eli Lilly (LLY) Stock Is Up, What You Need To Know",
    "summary": "Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.3% in the morning session after the company announced a partnership to develop a new oral obesity drug and was reported to be in advanced talks to acquire Ventyx Biosciences for over $1 billion.",
    "url": "https://finance.yahoo.com/news/eli-lilly-lly-stock-know-162128203.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "55f9f06d-3691-3902-ba05-daa930a3d7f9",
      "content": {
        "id": "55f9f06d-3691-3902-ba05-daa930a3d7f9",
        "contentType": "STORY",
        "title": "Eli Lilly (LLY) Stock Is Up, What You Need To Know",
        "description": "",
        "summary": "Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.3% in the morning session after the company announced a partnership to develop a new oral obesity drug and was reported to be in advanced talks to acquire Ventyx Biosciences for over $1 billion.",
        "pubDate": "2026-01-07T16:21:28Z",
        "displayTime": "2026-01-07T16:21:28Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/2d0b545c448821f8d1ada0dbe955b186",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "LLY Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/y7jUkGcVljBpqcrgSnimZQ--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/2d0b545c448821f8d1ada0dbe955b186.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/fw6rZdJZ6CRFkLxhDmPhew--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/2d0b545c448821f8d1ada0dbe955b186.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-lly-stock-know-162128203.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-lly-stock-know-162128203.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "VTYX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-07T18:00:00+00:00",
    "headline": "InduPro Therapeutics Announces Strategic Collaboration with Lilly to Develop First-in-Class Bispecific/Multispecific Oncology Therapeutics Using InduPro‚Äôs Proximity-Guided Platform",
    "summary": "SEATTLE & CAMBRIDGE, Mass., January 07, 2026--InduPro, Inc., a biotechnology company defining membrane protein spatial relationships to create novel therapeutics for the treatment of cancer and autoimmune diseases, today announced a global strategic collaboration and licensing agreement, and equity investment, with Eli Lilly and Company (\"Lilly\") to discover novel oncology treatments using InduPro‚Äôs proximity-guided platform.",
    "url": "https://finance.yahoo.com/news/indupro-therapeutics-announces-strategic-collaboration-180000974.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "40266270-3319-306b-8b3f-3df586d5d352",
      "content": {
        "id": "40266270-3319-306b-8b3f-3df586d5d352",
        "contentType": "STORY",
        "title": "InduPro Therapeutics Announces Strategic Collaboration with Lilly to Develop First-in-Class Bispecific/Multispecific Oncology Therapeutics Using InduPro‚Äôs Proximity-Guided Platform",
        "description": "",
        "summary": "SEATTLE & CAMBRIDGE, Mass., January 07, 2026--InduPro, Inc., a biotechnology company defining membrane protein spatial relationships to create novel therapeutics for the treatment of cancer and autoimmune diseases, today announced a global strategic collaboration and licensing agreement, and equity investment, with Eli Lilly and Company (\"Lilly\") to discover novel oncology treatments using InduPro‚Äôs proximity-guided platform.",
        "pubDate": "2026-01-07T18:00:00Z",
        "displayTime": "2026-01-07T18:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/2629db07b8846fe28892ca6a532109a8",
          "originalWidth": 480,
          "originalHeight": 480,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/v3s6_Y4ImqaUOsFaDOgUGg--~B/aD00ODA7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/2629db07b8846fe28892ca6a532109a8.cf.webp",
              "width": 480,
              "height": 480,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1jwJGWDeBW_U2O2oDXS1jw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/2629db07b8846fe28892ca6a532109a8.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/indupro-therapeutics-announces-strategic-collaboration-180000974.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/indupro-therapeutics-announces-strategic-collaboration-180000974.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-07T21:20:00+00:00",
    "headline": "3 Drug Stocks to Buy at a Discount",
    "summary": "The big news in the drug sector is the emergence of GLP-1 weight loss drugs, but dig deeper, and you'll find relatively cheap industry giants to consider.",
    "url": "https://www.fool.com/investing/2026/01/07/3-drug-stocks-to-buy-at-a-discount/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "ceb8fea2-15df-3ba3-9ab5-45ae1d883b70",
      "content": {
        "id": "ceb8fea2-15df-3ba3-9ab5-45ae1d883b70",
        "contentType": "STORY",
        "title": "3 Drug Stocks to Buy at a Discount",
        "description": "",
        "summary": "The big news in the drug sector is the emergence of GLP-1 weight loss drugs, but dig deeper, and you'll find relatively cheap industry giants to consider.",
        "pubDate": "2026-01-07T21:20:00Z",
        "displayTime": "2026-01-07T21:20:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/4f71bf990154afb24c7a9a05250a0185",
          "originalWidth": 1369,
          "originalHeight": 800,
          "caption": "A finger flipping dice that spell out long term and short term.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/A02CqIBRKDDimBJfuetC5Q--~B/aD04MDA7dz0xMzY5O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/4f71bf990154afb24c7a9a05250a0185.cf.webp",
              "width": 1369,
              "height": 800,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Nz1FKdFVpAkt9roiVdww2w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/4f71bf990154afb24c7a9a05250a0185.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/01/07/3-drug-stocks-to-buy-at-a-discount/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/3-drug-stocks-buy-discount-212000896.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-07T21:17:00+00:00",
    "headline": "Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases",
    "summary": "Eli Lilly and Company (NYSE: LLY) and Ventyx Biosciences, Inc. (Nasdaq: VTYX), a San Diego-based clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with inflammatory-mediated diseases, today announced entry into a definitive agreement for Lilly to acquire Ventyx.",
    "url": "https://finance.yahoo.com/news/lilly-acquire-ventyx-biosciences-advance-211700421.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "13ab1f34-25ab-30f3-b92f-9efe417616c8",
      "content": {
        "id": "13ab1f34-25ab-30f3-b92f-9efe417616c8",
        "contentType": "STORY",
        "title": "Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases",
        "description": "",
        "summary": "Eli Lilly and Company (NYSE: LLY) and Ventyx Biosciences, Inc. (Nasdaq: VTYX), a San Diego-based clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with inflammatory-mediated diseases, today announced entry into a definitive agreement for Lilly to acquire Ventyx.",
        "pubDate": "2026-01-07T21:17:00Z",
        "displayTime": "2026-01-07T21:17:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/df345efe9aaf8625c1224e8763d43e53",
          "originalWidth": 400,
          "originalHeight": 124,
          "caption": "(PRNewsfoto/Eli Lilly and Company)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/dqh2.OUhDnbMQOuq0T.AIQ--~B/aD0xMjQ7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/df345efe9aaf8625c1224e8763d43e53.cf.webp",
              "width": 400,
              "height": 124,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/wwDB4ilF3A4GGRE1cktfIw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/df345efe9aaf8625c1224e8763d43e53.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/lilly-acquire-ventyx-biosciences-advance-211700421.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/lilly-acquire-ventyx-biosciences-advance-211700421.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VTYX"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-07T20:47:07+00:00",
    "headline": "Sector Update: Health Care Stocks Gain Late Afternoon",
    "summary": "Health care stocks rose late Wednesday afternoon, with the NYSE Health Care Index adding 0.7% and th",
    "url": "https://finance.yahoo.com/news/sector-health-care-stocks-gain-204707424.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "70b57110-9ed2-3d9f-886a-6f8becadcc76",
      "content": {
        "id": "70b57110-9ed2-3d9f-886a-6f8becadcc76",
        "contentType": "STORY",
        "title": "Sector Update: Health Care Stocks Gain Late Afternoon",
        "description": "",
        "summary": "Health care stocks rose late Wednesday afternoon, with the NYSE Health Care Index adding 0.7% and th",
        "pubDate": "2026-01-07T20:47:07Z",
        "displayTime": "2026-01-07T20:47:07Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/sector-health-care-stocks-gain-204707424.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/sector-health-care-stocks-gain-204707424.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "VTYX"
            },
            {
              "symbol": "RVMD"
            },
            {
              "symbol": "XLV"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "VERA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-07T22:26:43+00:00",
    "headline": "Dow Jones Futures: Stock Market Fades From Highs; Eli Lilly, Google Lead New Buys",
    "summary": "The S&P 500 and Dow reversed from highs Wednesday, while the Nasdaq pared gains. Eli Lilly and Google flashed buy signals.",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-eli-lilly-google/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "e2c9a6ff-f5c0-3b9c-9e43-6b72385400a4",
      "content": {
        "id": "e2c9a6ff-f5c0-3b9c-9e43-6b72385400a4",
        "contentType": "STORY",
        "title": "Dow Jones Futures: Stock Market Fades From Highs; Eli Lilly, Google Lead New Buys",
        "description": "",
        "summary": "The S&P 500 and Dow reversed from highs Wednesday, while the Nasdaq pared gains. Eli Lilly and Google flashed buy signals.",
        "pubDate": "2026-01-07T22:26:43Z",
        "displayTime": "2026-01-07T22:26:43Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/e2c9a6ff-f5c0-3b9c-9e43-6b72385400a4/dow-jones-futures-stock.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/9ce1a96c65f43cb2567d90f94b20e497",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/5s9TlrXEGvo6f2yjWr3QjA--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/9ce1a96c65f43cb2567d90f94b20e497.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/5qXshpN1oJujuxnkmYfGOw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/9ce1a96c65f43cb2567d90f94b20e497.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-eli-lilly-google/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "GOOG"
            },
            {
              "symbol": "IDXX"
            },
            {
              "symbol": "BE"
            },
            {
              "symbol": "IONS"
            },
            {
              "symbol": "LGND"
            },
            {
              "symbol": "LGNXZ"
            },
            {
              "symbol": "LGNYZ"
            },
            {
              "symbol": "LGNZZ"
            },
            {
              "symbol": "BEIGF"
            },
            {
              "symbol": "ONC"
            },
            {
              "symbol": "^DJI"
            },
            {
              "symbol": "^IXIC"
            },
            {
              "symbol": "AAPL"
            },
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "GMED"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-07T22:18:52+00:00",
    "headline": "Lilly moves beyond blockbuster obesity drugs with $1.2 billion Ventyx buy",
    "summary": "By Puyaan Singh Jan 7 (Reuters) - Eli Lilly will buy autoimmune drug developer Ventyx Biosciences for $1.2 billion in cash, the companies said on Wednesday, marking the Zepbound maker's latest push to",
    "url": "https://finance.yahoo.com/news/eli-lilly-buy-ventyx-biosciences-212451835.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "39f0d233-2bd8-3126-913d-f92be58ba60d",
      "content": {
        "id": "39f0d233-2bd8-3126-913d-f92be58ba60d",
        "contentType": "STORY",
        "title": "Lilly moves beyond blockbuster obesity drugs with $1.2 billion Ventyx buy",
        "description": "",
        "summary": "By Puyaan Singh Jan 7 (Reuters) - Eli Lilly will buy autoimmune drug developer Ventyx Biosciences for $1.2 billion in cash, the companies said on Wednesday, marking the Zepbound maker's latest push to",
        "pubDate": "2026-01-07T22:18:52Z",
        "displayTime": "2026-01-07T22:18:52Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/0035a7cda85c0713d21b982f9a75c73d",
          "originalWidth": 800,
          "originalHeight": 534,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8IhSg0foRMSO8.iQTIFkmw--~B/aD01MzQ7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/0035a7cda85c0713d21b982f9a75c73d.cf.webp",
              "width": 800,
              "height": 534,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/N3sVJw6pS5wCV.N3clBe6g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/0035a7cda85c0713d21b982f9a75c73d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-buy-ventyx-biosciences-212451835.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-buy-ventyx-biosciences-212451835.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VTYX"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-07T21:49:27+00:00",
    "headline": "Eli Lilly, IBD Stock Of The Day, Offers Two Entries On Rumored Buyout Rally",
    "summary": "Eli Lilly is Wednesday's IBD Stock Of The Day. Shares are breaking above a pair of bases as rumors swirl about a potential Ventyx buyout.",
    "url": "https://www.investors.com/research/ibd-stock-of-the-day/eli-lilly-ibd-stock-of-the-day-offers-two-entries-on-rumored-buyout-rally/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "35e8b5ac-f25c-3395-8485-ae70792425a2",
      "content": {
        "id": "35e8b5ac-f25c-3395-8485-ae70792425a2",
        "contentType": "STORY",
        "title": "Eli Lilly, IBD Stock Of The Day, Offers Two Entries On Rumored Buyout Rally",
        "description": "",
        "summary": "Eli Lilly is Wednesday's IBD Stock Of The Day. Shares are breaking above a pair of bases as rumors swirl about a potential Ventyx buyout.",
        "pubDate": "2026-01-07T21:49:27Z",
        "displayTime": "2026-01-07T21:49:27Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/35e8b5ac-f25c-3395-8485-ae70792425a2/eli-lilly-ibd-stock-of-the.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/00354e83d8b927b403115c9bcc44f205",
          "originalWidth": 816,
          "originalHeight": 430,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/wztD5iALnI78L9nafEZqng--~B/aD00MzA7dz04MTY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/00354e83d8b927b403115c9bcc44f205.cf.webp",
              "width": 816,
              "height": 430,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/sZFcaPOCpwtdjNW.HRdfLQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/00354e83d8b927b403115c9bcc44f205.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/research/ibd-stock-of-the-day/eli-lilly-ibd-stock-of-the-day-offers-two-entries-on-rumored-buyout-rally/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "VTYX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]